- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Weekly Roundup: July 19-23
ICYMI, some of this week’s featured content includes systemic treatment for pediatric AD, a new video game for dermatologists, St. Jude's registry for pediatric melanoma, and more.
POLL: Which way do you prefer to learn about the latest updates in dermatology?
Systemic Treatment for Pediatric AD
New and forthcoming options bring opportunity for optimizing patient care.
New Video Game Aimed at Dermatologist Education
Level Ex has announced its Top Derm Game as its expansion into the dermatology specialty.
St. Jude Registry Aims to Better Understand Pediatric Melanoma
St. Jude Children’s Research Hospital researchers have created a registry to better understand pediatric melanoma.
Alma Hybrid Laser Receives FDA 510(k) Clearance
Alma today announces the FDA clearance of its Alma Hybrid combination platform, which includes an ablative 10,600 nm (CO2) laser and nonablative 1570 nm laser for skin resurfacing.
Mastering Game Changers in Psoriasis
Engage patients in treatment compliance and lifestyle changes to achieve optimal outcomes.
Chat Room Referral Could Redefine the Physician-Patient Relationship
In this month's Legal Eagle column, David J. Goldberg, MD, JD, explores chat room referrals and how they could possibly alter the physician-patient relationship.
FDA Decision Delayed for Baricitinib for Atopic Dermatitis
The FDA has decided to delay the PDUFA goal date for baricitinib for treatment of adults with moderate to severe atopic dermatitis.
Psoriasis Strategies in Skin of Color
Addressing underdiagnosis, underrepresentation, and undertreatment in skin of color patients with psoriasis.
FDA Delays Approval for Abrocitinib for Atopic Dermatitis
The FDA did not meet the PDUFA goal date for abrocitinib (PF-04965842; Pfizer), a potential treatment of moderate to severe atopic dermatitis in adults and adolescents.
The Cutaneous Connection: Episode 27- Benzene Contamination Update
Christoper Bunick, MD, PhD, provides an update on benzene contamination in sunscreen, including a recent recall from Johnson & Johnson.
In this month's Cosmetic Conundrums column, Dermatology Times® Chief Medical Editor Zoe Diana Draelos, MD, explores the world of eyebrows, including microblading, grooming, and shape.
Biologics for Psoriasis May Increase Serious Infection Risk
Gastrointestinal infections were the most common serious infections associated with biologics, according to a cohort analysis.
The Mainstream Patient: July 23, 2021
This week’s edition of The Mainstream Patient features stories about a new TikTok-inspired acne treatment, skin care ingredient absorption, injectable psoriasis treatments, plus more.
